Breaking News

Germany Defeats Argentina for Fourth World Cup Title
Tweet TWEET

The Zacks Analyst Blog Highlights: Viacom, Facebook, Apple, Google and Bayer

 The Zacks Analyst Blog Highlights: Viacom, Facebook, Apple, Google and Bayer

PR Newswire

CHICAGO, June 10, 2013

CHICAGO, June 10, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Viacom Inc. (Nasdaq:VIAB-Free
Report), Facebook Inc. (Nasdaq:FB-Free Report), Apple Inc. (Nasdaq:AAPL-Free
Report), Google Inc. (Nasdaq:GOOG-Free Report) and Bayer (OTC:BAYRY-Free
Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Friday's Analyst Blog:

Comedy Central Launched as iOS App

Media and film producing company, Viacom Inc. (Nasdaq:VIAB-Free Report) has
released an iOS app of its popular channel COMEDY CENTRAL, which will allow
users to select and watch stand-up comedy from its extensive library of
content.

The app is named CC: Stand Up and is an extension of COMEDY CENTRAL, which is
the leading comedy brand that allows users to view comic content without
interruptions. Users of the iOS app can stream video footage from a collection
of 6000 videos performed by 700 comedians.

The most innovative feature of this app is its Six degrees of Stand-Up, which
uses a powerful recommendation tool to suggest related videos and comedians to
the users. The suggestions will be based on sensibilities, topic and genre.
Additionally, the new app will let users share comic videos via social media
sites likeFacebook Inc. (Nasdaq:FB-Free Report) and Twitter.

Apple Inc.'s (Nasdaq:AAPL-Free Report) iPhone and iPad customers can avail the
application for free from the App store. Viacom is currently developing the
application for Google Inc.'s (Nasdaq:GOOG-Free Report) Android operating
system.

Nowadays, comedy shows are very popular, particularly among the youth and with
CC: Stand Up, they will be able to view the talent of various comedians other
than the mainstream stand-up artists. The new app will be promoted on all
COMEDY CENTRAL product wings like COMEDY CENTRAL Radio, comedy central
certified clubs and COMEDY CENTRAL Live Entertainment.

In the recently concluded quarter, Viacom's Media Network Segment reported
subdued growth, where revenues inched up a mere 2%. We believe that launching
COMEDY CENTRAL as an iOS app will widen the reach of the channel globally,
which in turn will enhance the segment's advertising prospect.

Viacom currently carries a Zacks Rank #3 (Hold).

Positive Data on Bayer Eye Drug

The HealthCare segment of Bayer (OTC:BAYRY-Free Report) recently announced
positive top-line results from the phase III MYRROR study on VEGF Trap-Eye
(aflibercept ophthalmic solution) in patients suffering from myopic choroidal
neovascularization (mCNV).

Bayer now intends to submit its first regulatory approval application in Asia
for VEGF Trap-Eye in this indication in the latter half of the year. Bayer
also plans to present data from the MYRROR study at an upcoming medical
conference.

Results from the study showed that patients who received 2 milligrams (mg)
dose of VEGF Trap-Eye experienced a mean improvement in best-corrected visual
acuity (BCVA) from baseline of 12.1 letters compared to a loss of 2 letters in
patients who were administered sham injections. The candidate was also well
tolerated during the study.

Conjunctival hemorrhage, dry eye, eye pain, headache and nasopharyngitis were
some of the most common adverse events observed during the study.

We note that VEGF Trap-Eye is already approved in the US, under the trade name
Eylea, for the treatment of neovascular (wet) age-related macular degeneration
(AMD). The drug was later approved for the treatment of macular edema
following central retinal vein occlusion (CRVO) as well. The drug is also
approved for the wet AMD indication in Japan, Australia, Europe and several
other countries.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Pros.

Get the full Report on VIAB - FREE
Get the full Report on FB - FREE
Get the full Report on AAPL - FREE
Get the full Report on GOOG - FREE
Get the full Report on BAYRY - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com